Patient-level costing analysis of paediatric short bowel syndrome care in a specialist tertiary centre

Jones, Brendan C.; O'Sullivan, Benjamin; Amin, Sonal Parmar; Hill, Susan; Eaton, Simon; Coppi, Paolo De

doi:10.1007/s00383-022-05074-6

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering all pediatric SBS-IF-patients, the total average cost of hospital-based HCRU was €221,000 for the first year and €57,000 annually. The annual cost corresponded surprisingly well with the previously observed in the United Kingdom (£52,800) ( 24 ). The costs were even higher for the early preterm patients with SBS-IF.…”

Section: Discussionsupporting

confidence: 89%

Pediatric Short Bowel Syndrome: Real-World Evidence on Incidence and Hospital Resource Use From a Finnish Data Lake

Puttonen

Tuominen²,

Ukkola-Vuoti³

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

Objectives: Little is known about the epidemiology and healthcare burden of pediatric intestinal failure (IF). We aimed to assess the incidence, prevalence, healthcare resource utilization (HCRU) and related costs of pediatric short bowel syndrome (SBS) using follow-up data from the largest hospital district in Finland. Methods: This retrospective registry study utilized electronic healthcare data covering all pediatric patients with SBS-IF born between 2010 and 2019 at the Hospital District of Helsinki and Uusimaa in Finland. Patients were followed from birth until the end of 2020 and compared to control patients, all from the same hospital system. Results: In total, 38 patients with SBS-IF and 1:5 matched controls were included, with median follow-up time of almost six years from birth. Over half of the patients were born early preterm (gestational age ≤30 weeks). The incidence of pediatric SBS-IF was 24 per 100,000 live births. The HCRU was higher compared to controls and most of the inpatient days incurred during the first year of the SBS-IF patients’ life. The average hospital-based HCRU costs were €221,000 for the first year and €57,000 for whole follow-up annually. The costs were higher for the early preterm patients and accumulated mainly from inpatient days. Conclusions: SBS-IF is a rare disease with a relatively low number of patients treated at each hospital district. The burden on the hospital system, as well as the patient’s family, is especially high at the onset as the newborns with SBS-IF spend a significant part of their first year of life in the hospital.

show abstract

Section: Discussionsupporting

confidence: 89%

Pediatric Short Bowel Syndrome: Real-World Evidence on Incidence and Hospital Resource Use From a Finnish Data Lake

Puttonen

Tuominen²,

Ukkola-Vuoti³

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

show abstract

“…There is currently an economic debate as to whether the cost of TED is greater than the costs of PN and management of complications (186). However, if a child fully weans from PN the benefit to the child from losing their CVC and freedom from highly technical treatment with a near normal life expectancy would be expected to outweigh the cost.…”

Section: Treatment For Enhancing Intestinal Absorptionmentioning

confidence: 99%

Nutrition and Intestinal Rehabilitation of Children With Short Bowel Syndrome: A Position Paper of the ESPGHAN Committee on Nutrition. Part 2: Long-Term Follow-Up on Home Parenteral Nutrition

Norsa,

Goulet,

Alberti

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

Self Cite

View full text Add to dashboard Cite

Short bowel syndrome (SBS) is the leading cause of intestinal failure (IF) in children. The preferred treatment for IF is parenteral nutrition which may be required until adulthood. The aim of this position paper is to review the available evidence on managing SBS and to provide practical guidance to clinicians dealing with this condition. All members of the Nutrition Committee of the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) contributed to this position paper. Some renowned experts in the field joined the team to guide with their expertise. A systematic literature search was performed from 2005 to May 2021 using PubMed, MEDLINE, and Cochrane Database of Systematic Reviews. In the absence of evidence, recommendations reflect the expert opinion of the authors. Literature on SBS mainly consists of retrospective single-center experience, thus most of the current papers and recommendations are based on expert opinion. All recommendations were voted on by the expert panel and reached >90% agreement. This second part of the position paper is dedicated to the long-term management of children with SBS-IF. The paper mainly focuses on how to achieve intestinal rehabilitation, treatment of complications, and on possible surgical and medical management to increase intestinal absorption.

show abstract

Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome

Gattini,

Belza,

Kraus

et al. 2023

Clinical Nutrition

View full text Add to dashboard Cite

Patient-level costing analysis of paediatric short bowel syndrome care in a specialist tertiary centre

Cited by 3 publications

References 29 publications

Pediatric Short Bowel Syndrome: Real-World Evidence on Incidence and Hospital Resource Use From a Finnish Data Lake

Pediatric Short Bowel Syndrome: Real-World Evidence on Incidence and Hospital Resource Use From a Finnish Data Lake

Nutrition and Intestinal Rehabilitation of Children With Short Bowel Syndrome: A Position Paper of the ESPGHAN Committee on Nutrition. Part 2: Long-Term Follow-Up on Home Parenteral Nutrition

Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome

Contact Info

Product

Resources

About